[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
…, K Abeyskera, J Aboagye, M Adam, K Adams… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
…, KWM Abeyskera, J Aboagye, M Adam, K Adams… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled …
…, T Lambe, SC Gilbert, AJ Pollard, J Aboagye, K Adams… - The Lancet, 2020 - thelancet.com
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
…, S Warren, S Varkonyi-Clifford, S Saich, K Adams… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
Chemokine receptors and their role in inflammation and infectious diseases
Chemokines are small peptides that are potent activators and chemoattractants for leukocyte
subpopulations and some nonhemopoietic cells. Their actions are mediated by a family of 7…
subpopulations and some nonhemopoietic cells. Their actions are mediated by a family of 7…
Determining the appropriate response to evidence of public concern: the case of food safety
A Finn, JJ Louviere - Journal of Public Policy & Marketing, 1992 - journals.sagepub.com
With social issues again close to the top of the research agenda for marketers, policy makers
are increasingly likely to be presented public opinion research findings that suggest the …
are increasingly likely to be presented public opinion research findings that suggest the …
[HTML][HTML] Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials …
Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …
immunity in some countries as the interval between the first and second dose becomes …
[HTML][HTML] Valganciclovir for symptomatic congenital cytomegalovirus disease
…, JA Bocchini, PH Dennehy, A Finn… - … England Journal of …, 2015 - Mass Medical Soc
Background The treatment of symptomatic congenital cytomegalovirus (CMV) disease with
intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 …
intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 …
Clinical spectrum of X-linked hyper-IgM syndrome
…, L Hammarstrom, T Abrahamsen, A Jones, A Finn… - The Journal of …, 1997 - Elsevier
We report the clinical and immunologic features and outcome in 56 patients with X-linked
hyper-IgM syndrome, a disorder caused by mutations in the CD40 ligand gene. Upper and …
hyper-IgM syndrome, a disorder caused by mutations in the CD40 ligand gene. Upper and …
